Pan W, Chen XP, Su S, Tao ZH. Bortezomib regulates NF-κB and TGF-β1 expression in hepatic fibrosis in a rat model.
Shijie Huaren Xiaohua Zazhi 2015;
23:894-900. [DOI:
10.11569/wcjd.v23.i6.894]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
AIM: To assess the protective effect of the proteasome inhibitor bortezomib on liver fibrosis in rats and to explore the possible mechanism.
METHODS: Thirty SD rats were randomized into three groups: a normal diet group (ND group), a liver fibrosis group (LF group) and a bortezomib group (Bor group). After treatment, the rats in each group were sacrificed. Hepatic fibrosis was assessed by HE and Masson trichrome staining. The expression of nuclear factor-kappa B (NF-κB) p65 was assessed by immunohistochemistry. Real-time PCR was employed to detect the transforming growth factor β1 (TGF-β1) mRNA level in liver samples. The expression of TGF-β1 protein was determined by Western blot analysis.
RESULTS: The hepatic fibrosis level in the Bor group was significantly lower than that in the LF group as revealed by HE and Masson staining. The positive rate of NF-κB p65 subunit was significantly lower in the Bor group than in the LF group (4.72 vs 9.05, P < 0.05). The expression of TGF-β1 mRNA was significantly lower in the Bor group than in the LF group (0.96 vs 1.64, P < 0.05). The expression of TGF-β1 protein was also significantly lower in the Bor group than in the LF group (1.34 vs 1.72, P < 0.05).
CONCLUSION: These findings suggest that bortezomib reduces hepatocyte injury in rats with hepatic fibrosis possibly by suppression of NF-κB activation and TGF-β1 expression.
Collapse